Categories: Automobile

NEXEN TIRE Supplies OE Tires for Hyundais NextGeneration Hydrogen SUV, The allnew NEXO

  • Premium comfort tire ‘N’FERA Supreme S’ selected as OE for Hyundai’s advanced hydrogen SUV
  • Tire purpose-built with AI-driven design for superior quietness, durability, and stability

SEOUL, South Korea, Jul 9, 2025 – NEXEN TIRE, a leading global tire manufacturer, announced today that its premium comfort tire N’FERA Supreme S has been selected as original equipment (OE) for Hyundai Motor Company’s next-generation hydrogen fuel cell electric vehicle (FCEV), The all-new NEXO.

- Advertisement -

This marks the first full model change for the NEXO in seven years. ‘The all-new NEXO’ features an upgraded hydrogen powertrain with a driving range exceeding 700 kilometers per charge, an enhanced quiet ride, and a sustainability-focused interior and exterior design. In line with these advanced characteristics, the N’FERA Supreme S was chosen to deliver optimal performance in terms of noise reduction, high load capacity, and driving stability.

- Advertisement -

Specifically engineered for high-performance hydrogen-powered SUVs, the N’FERA Supreme S offers exceptional durability and responsive handling. The tire incorporates an AI-enhanced load distribution structure and high-rigidity sidewalls, ensuring stable grip and steering – particularly important for the heavy-load configuration of The all-new NEXO. Additionally, the tire features ‘Level Keeping Technology’, which maintains consistent performance even after 50% tread wear.

- Advertisement -

Its aerodynamic tread design reduces both air drag and rolling resistance, helping to improve overall fuel economy while supporting strong braking and high-speed handling performance.

- Advertisement -

To complement the NEXO’s quiet hydrogen drivetrain, the N’FERA Supreme S integrates a suite of noise-reduction technologies. These include the Noise Reduction System (NRS), which uses sound-absorbing materials inside the tire cavity to minimize in-vehicle noise, and AI-based tread pattern optimization – developed through big data analysis – to reduce road noise under diverse driving conditions. Together, these innovations offer a noticeably quieter and more refined driving experience.

- Advertisement -

NEXEN TIRE continues to grow its presence in the global OE market, strengthening partnerships with leading automakers like Hyundai and expanding supply to major regions including Europe and North America.  By developing advanced solutions for electric, hydrogen, and internal combustion vehicles, NEXEN TIRE is proactively responding to the evolving demands of the mobility industry.

- Advertisement -

 “This latest supply agreement highlights NEXEN TIRE’s technological leadership in the next generation of eco-friendly mobility,” said John Bosco (Hyeon Suk) Kim, CEO of NEXEN TIRE. ”We will continue to broaden our global OE partnerships by delivering optimized tire solutions for all powertrains – hydrogen fuel cell, electric, hybrid, and internal combustion alike.”

- Advertisement -
TheNews Market

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

4 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

4 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

4 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

4 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

4 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

4 hours ago